2B30 Stock Overview
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.61 |
| 52 Week High | US$2.96 |
| 52 Week Low | US$1.36 |
| Beta | 1.11 |
| 1 Month Change | -16.68% |
| 3 Month Change | -28.85% |
| 1 Year Change | -21.94% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2B30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.2% | -3.1% | -2.0% |
| 1Y | -21.9% | -31.9% | -0.3% |
Return vs Industry: 2B30 exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: 2B30 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 2B30 volatility | |
|---|---|
| 2B30 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2B30's share price has been volatile over the past 3 months.
Volatility Over Time: 2B30's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 377 | Paul Edick | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| 2B30 fundamental statistics | |
|---|---|
| Market cap | €229.43m |
| Earnings (TTM) | -€58.44m |
| Revenue (TTM) | €153.88m |
1.5x
P/S Ratio-4.0x
P/E RatioIs 2B30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2B30 income statement (TTM) | |
|---|---|
| Revenue | US$163.91m |
| Cost of Revenue | US$28.65m |
| Gross Profit | US$135.27m |
| Other Expenses | US$197.52m |
| Earnings | -US$62.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 82.52% |
| Net Profit Margin | -37.98% |
| Debt/Equity Ratio | -2,815.3% |
How did 2B30 perform over the long term?
See historical performance and comparison